MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Home・Akciju saraksts・Biogen Inc

Biogen Inc

Slēgts

SektorsVeselības aprūpe

146.67 2.61

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

142.5

Max

147.35

Galvenie mērījumi
By Trading Economics
Ienākumi	394M 635M
Pārdošana	215M 2.6B
P/E Sektora vidējais	13.846 36.442
Peļņas marža	23.995
Darbinieki	7,605
EBITDA	457M 1B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+22.99% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 30. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.3B 21B
Iepriekšējā atvēršanas cena	144.06
Iepriekšējā slēgšanas cena	146.67

Ziņu noskaņojums

By Acuity

10%

90%

11 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

118.15 / 121.17 Atbalsts un pretestība

Biogen Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 20. okt. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

2025. g. 20. okt. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 20. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

2025. g. 20. okt. 22:14 UTC

Tirgus saruna

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

2025. g. 20. okt. 22:00 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

2025. g. 20. okt. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

2025. g. 20. okt. 20:56 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

2025. g. 20. okt. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 20. okt. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 20. okt. 20:38 UTC

Peļņas

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

2025. g. 20. okt. 20:38 UTC

Peļņas

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

2025. g. 20. okt. 20:38 UTC

Peļņas

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

2025. g. 20. okt. 20:36 UTC

Peļņas

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

2025. g. 20. okt. 20:36 UTC

Peļņas

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

2025. g. 20. okt. 20:36 UTC

Peļņas

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

2025. g. 20. okt. 20:36 UTC

Peļņas

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

2025. g. 20. okt. 20:16 UTC

Tirgus saruna

Canada Labor-Market Indicators Lean Dovish -- Market Talk

2025. g. 20. okt. 20:05 UTC

Peļņas

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

2025. g. 20. okt. 19:39 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

2025. g. 20. okt. 19:34 UTC

Tirgus saruna

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

2025. g. 20. okt. 19:32 UTC

Tirgus saruna

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

2025. g. 20. okt. 19:00 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

2025. g. 20. okt. 18:29 UTC

Tirgus saruna

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

2025. g. 20. okt. 18:11 UTC

Tirgus saruna

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

2025. g. 20. okt. 18:04 UTC

Tirgus saruna

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

2025. g. 20. okt. 17:03 UTC

Tirgus saruna

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

2025. g. 20. okt. 17:01 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 20. okt. 17:01 UTC

Tirgus saruna

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

2025. g. 20. okt. 16:43 UTC

Tirgus saruna

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

2025. g. 20. okt. 16:25 UTC

Tirgus saruna

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Salīdzinājums

Cenas izmaiņa

Biogen Inc Prognoze

Cenas mērķis

By TipRanks

22.99% augšup

Prognoze 12 mēnešiem

Vidējais 175.88 USD 22.99%

Augstākais 224 USD

Zemākais 118 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Biogen Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

23 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 23 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Biogen Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

118.15 / 121.17Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

11 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.